Why Is Laurus Labs Share Price Falling? Key Reasons & Share Price Target

Fri Apr 10 2026

Laurus Labs is trading at Rs 380, down 45% from its 52-week high of Rs 650. The sustained fall in the Laurus Labs share price has unsettled investors who built positions during the stock’s rally phase. At its current price, the stock is approaching its 52-week low of Rs 340, and the market is asking one question loudly: is this a buying opportunity, or is the decline a warning sign of deeper problems?

The Laurus Labs share price falling is not random. There are specific, identifiable factors driving institutional selling, retail panic, and analyst downgrades — and this article examines each of them with real data from the latest quarterly results and exchange filings.

[Click Here – Get Free Investment Predictions](https://univest.in/user/log-in)

This article covers every key reason behind the Laurus Labs share price fall, the latest financial performance data, technical levels to watch, institutional positioning, and what analysts think the Laurus Labs share price target is for 2026.

Table of Contents

About Laurus Labs

[Click Here – Get Free Investment Predictions on Univest.

Laurus Labs is a listed company in the Pharmaceuticals / CDMO sector with a market capitalisation of Rs 20,500 Cr. The stock trades at approximately 32x trailing P/E and 4.2x price-to-book. Its 52-week range spans from Rs 340 to Rs 650, and the current price of Rs 380 puts the stock in the lower quarter of that range, reflecting the sustained selling pressure of recent months.

Why Is Laurus Labs Share Price Falling? Key Reasons

Laurus Labs Share Price Falling, Key Data 2026

[Tap to Access Best Research Pieces on Univest.

API Business Margin Collapse — Pricing Pressure from China

Laurus Labs’ core API (Active Pharmaceutical Ingredient) business, which contributes approximately 45% of revenue, has faced severe pricing pressure from Chinese API manufacturers. China’s API exporters have been aggressively pricing ARV (Antiretroviral) and other generic APIs at levels that Laurus cannot match without sacrificing margins. The result is a PAT margin compression from 9-10% to 4-5% in the current cycle.

ARV APIs, which are the cornerstone of Laurus’s API business, have seen prices decline 20-25% over the past 18 months due to overcapacity in the global generic ARV market. Donor-funded procurement agencies are leveraging this competition to extract lower prices, directly impacting Laurus’s realisation.

CDMO Business Ramp-Up Slower Than Expected

Laurus had pivoted aggressively toward CDMO (Contract Development and Manufacturing Organisation) services as a higher-margin alternative to the commoditised API business. The CDMO segment has been ramping up, but the pace has been slower than investor expectations. Large CDMO contracts from global pharma companies take 18-24 months from contract signing to meaningful revenue contribution.

Working Capital Intensity

Laurus Labs has been investing heavily in CDMO capacity at its Vizag facilities, creating higher capital expenditure and working capital requirements. The combination of margin compression and high capex has led to declining free cash flow, which is a concern for a company valued at 32x trailing earnings.

Laurus Labs Latest News That Impacted the Stock

August 2025: Q1 FY26: PAT falls 48% YoY on API pricing pressure.

November 2025: Q2 FY26: CDMO revenues grow 25% but PAT remains suppressed.

January 2026: Q3 FY26: PAT Rs 67 Cr (-51% YoY); management guides for recovery in FY27.

February 2026: Stock hits 52-week low Rs 340 on weak guidance.

March 2026: New CDMO facility at Vizag commissioned; first batches for Phase 3 trials.

Laurus Labs Financial Performance Analysis

The quarterly financial data for Laurus Labs provides important context for understanding why the share price is falling. The numbers below highlight the key metrics that institutional analysts track closely.

Key Metric	Latest Quarter	Year-Ago Quarter	YoY Change
Revenue	Rs 1,532 Cr	Rs 1,414 Cr	+8.3% YoY
Net Profit (PAT)	Rs 67 Cr	Rs 138 Cr	-51% YoY
Market Cap	Rs 20,500 Cr	—	Current
P/E Ratio	32x	—	Trailing
P/B Ratio	4.2x	—	Current

If you want to track Laurus Labs’s financial metrics in real time, check the Univest Screener for live data, peer comparisons, and financial history.

Technical Signals: What the Charts Are Saying

Laurus Labs is trading at Rs 380, below all key moving averages including the 50-day, 100-day, and 200-day MAs. The stock has formed a clear pattern of lower highs and lower lows since its 52-week high of Rs 650. Key support is at the 52-week low of Rs 340. Resistance is at Rs 360 in the near term.

Download the Univest iOS App or Univest Android App to track Laurus Labs’s live price and get daily research insights.

Market Sentiment and Institutional Positioning

Promoter holding stands at 27.2%, which is relatively modest and suggests limited promoter confidence buffer in volatile markets. FII holding at 22.6% is significant, meaning global risk-off sentiment disproportionately impacts the stock, and DII holding at 28.4% indicates domestic institutions have meaningful exposure.

High FII ownership in any stock creates downside amplification when global risk appetite contracts. The Laurus Labs share price falling has been exacerbated by FII selling that is driven by macro factors — crude oil, dollar strength, US rate expectations — rather than company-specific concerns alone.

Future Outlook: Can Laurus Labs Recover?

Laurus Labs’ long-term CDMO thesis remains intact. The company has invested significantly in infrastructure and capability that will begin contributing meaningfully from FY28 onwards. In the near term, API margin pressure will persist until Chinese overcapacity unwinds. At 32x trailing P/E on deeply suppressed earnings, the stock appears expensive. However, at 15-18x FY28 earnings (when CDMO ramp-up is expected to be substantial), the stock looks attractively priced. Patient investors with a 2-year horizon may find this a compelling bet.

Laurus Labs Share Price Target 2026

Subscribe to Univest Pro for Premium Stock Research and F&O Setups.

Short-Term Target (3-6 Months)

In the short term, Laurus Labs share price target is Rs 360-420 based on current technical positioning and near-term fundamental catalysts. The downside risk if the 52-week low of Rs 340 breaks is approximately 5-10% further.

12-Month Analyst Target

Analyst consensus 12-month Laurus Labs share price target is Rs 480-560, implying significant upside from the current price of Rs 380. This target assumes a partial recovery of the factors driving the current decline.

Long-Term Target (FY27-FY28)

In a recovery scenario where the key headwinds resolve, the Laurus Labs share price target for FY28 is Rs 650-800. This long-term bull case requires the fundamental concerns addressed in this article to show measurable improvement over the next 6-12 quarters.

For live Laurus Labs tracking and peer comparison, explore the Univest Screener.

Conclusion

Laurus Labs share price is falling due to a combination of company-specific headwinds and broader market pressures. The 52-week decline of 45% from the high of Rs 650 to the current Rs 380 has created both a risk and an opportunity. The risk is that the concerns identified in this article deepen; the opportunity is that the stock is now meaningfully cheaper than it was at the peak. Analyst consensus targets of Rs 480-560 for 12 months and Rs 650-800 for the longer term suggest significant potential upside for patient investors.

This article is for informational purposes only. Please conduct your own research and consult a SEBI-registered financial advisor before making any investment decisions.

Frequently Asked Questions

Q1. Why is Laurus Labs share price falling in 2026?

Laurus Labs share price is falling due to the reasons detailed in this article, including sector-specific headwinds, recent financial performance concerns, and broader market pressures. The stock has fallen 45% from its 52-week high of Rs 650 to its current price of Rs 380. Investors should review all factors and consult a SEBI-registered financial advisor before making investment decisions.

Q2. What is Laurus Labs share price target?

The 12-month analyst consensus Laurus Labs share price target is Rs 480-560. The short-term target for 3-6 months is Rs 360-420, while the long-term target for FY27-FY28 is Rs 650-800 in a recovery scenario. These are analyst projections and not guaranteed returns.

Q3. Should I buy Laurus Labs shares now?

This article cannot provide personalised investment advice. Laurus Labs is trading at Rs 380 with a 52-week range of Rs 340 to Rs 650. Analyst consensus targets suggest potential upside. However, all the risks outlined in this article remain live. Consult a SEBI-registered financial advisor for personalised advice.

Q4. What is Laurus Labs’s market cap and PE ratio?

Laurus Labs’s current market capitalisation is Rs 20,500 Cr with a trailing P/E of 32x and price-to-book ratio of 4.2x. The stock is trading at Rs 380 as of April 2026.

Q5. What are Laurus Labs’s latest quarterly results?

In the most recent quarter, Laurus Labs reported revenue of Rs 1,532 Cr (+8.3% YoY) and net profit (PAT) of Rs 67 Cr (-51% YoY). Full quarterly financial data is available on the NSE/BSE filing portals and on the Univest Screener.

Q6. Who holds Laurus Labs shares institutionally?

Laurus Labs’s shareholding: Promoters 27.2%, FIIs 22.6%, DIIs 28.4%. High FII ownership creates sensitivity to global risk-off sentiment. Check the latest quarter’s shareholding pattern on NSE/BSE for the most current data.

Q7. What can trigger a recovery in Laurus Labs share price?

Key recovery triggers for Laurus Labs include: improvement in the fundamental factors causing the current decline, positive quarterly results showing reversal of the stressed metrics, broad market recovery, and any sector-specific positive news. Monitor developments closely.

Q8. What is the 52-week low of Laurus Labs share price?

Laurus Labs’s 52-week low is Rs 340, reached during the recent market correction. The 52-week high was Rs 650. The current price of Rs 380 represents a fall of 45% from the 52-week high. Technical analysts identify Rs 340 as a key support level.

For more analysis on falling stocks, visit Univest Blogs.